RISK ASSESSMENT AND MONITORING - EXPERIENCE FROM PHILEMON
|
|
- Brice Black
- 6 years ago
- Views:
Transcription
1 RSK ASSESSMENT AND MONTORNG - EXPERENCE FROM PHEMON AU UNVERSTET HEATH BRGTTE ORK SCHEMMER GCP-KOORDNATOR 22. OKTOBER 2015
2 Mantle Cell ymphoma Working Group: Designs and runs clinical trials
3 NG-MC6 - PHEMON PHase brutinib Enalidomide MONtle Cell ymphoma A phase non-randomised, open-label multicenter trial in relapsed/refractory MC Primary endpoint Maximal overall response rate with PET and CT (ORR)
4 PHEMON treatment outline R R R R R R R R R R R R Weeks 12 nduction cycles Maintenance until progression
5 PHEMON organisation CTO Aarhus Mats Jerkeman, P und, Sponsor Sweden Mats Jerkeman National P Norway Arne Kolstad National P Finland Riikka Räty National P Denmark Martin Hutchings National P und Uppsala Oslo Trondheim Helsinki Oulu Rigshospitalet Odense Aalborg Aarhus
6 PHEMON in summary Phase study 4 Nordic countries, 10 sites imited budget Central coordination by CTO How do we fulfill the sponsor obligation of monitoring?
7 Monitoring in PHEMON Established good collaboration with local GCP unit and with several other Nordic academic units Centralised coordination preferred
8 TMENE FOR THE COOPERATON N PHEMON May First PHEMON trial meeting in Aarhus (sponsor from Sweden, CTO, GCP-unit) t was decided to use the Nordic Monitoring Network, NORM Sept Second trial meeting in Aarhus (sponsor from Sweden, CTO, GCP-unit) The Danish risk assessment was prepared for discussion before the meeting Nov Third trial meeting on Skype (sponsor and CTO) t was decided that the monitoring plan should be the same in all the Nordic countries and should be prepared according to the NORM guideline March 2015 Mail correspondence with sponsor and CTO about first version of RAT (risk assessment tool for a coordinated GCP-monitoring) and the monitoring plan April 2015 Start meeting AU UNVERSTET HEATH BRGTTE ORK SCHEMMER GCP-KOORDNATOR 22. OKTOBER 2015
9 PHEMON TRA MEETNG MAY 2014 First meeting in Aarhus (sponsor from Sweden, Helle Toldbod from CTO, Marianne E and Birgitte S from the GCP-unit) Not only to discuss monitoring it was just a small part of the meeting But among others - it was decided to use the Nordic Monitoring Network, NORM to identify monitors in Norway, Sweden, Finland and Denmark At this point the monitoring guideline including RAT wasn t available yet t was planned that before the next meeting sponsor should send his proposal for a monitoring plan and that the GCP-unit should use this to prepare a draft for a monitoring plan AU UNVERSTET HEATH BRGTTE ORK SCHEMMER GCP-KOORDNATOR 22. OKTOBER 2015
10 PHEMON TRA MEETNG SEPT Second trial meeting in Aarhus (sponsor from Sweden, Helle Toldbod from CTO, legal advisor Susanne Kudsk, Marianne E and Birgitte S from GCP-unit) Again monitoring was just a part of the agenda The Danish risk assessment template was prepared for discussion before the meeting t was filled in by Marianne and With several questions to discuss ssues to think about The documents were sent to sponsor and CTO (Helle Toldbod) ahead of the meeting AND. AU UNVERSTET HEATH BRGTTE ORK SCHEMMER GCP-KOORDNATOR 22. OKTOBER 2015
11 WHAT CAME UP N SEPT. 2014? ength of monitoring period: 2 yrs inclusion period ( ) + 3 yrs follow-up period ( ). n total 5 yrs. Organisation: A responsibility split should be prepared Data: Comparable results: Use of Deauville criteria for PET evaluations will be added to the protocol and to the CRF A comment field should be available in the CRF for registration of protocol deviations t was discussed if monitoring should be performed on any parts of the MRD data? e.g. manual data entry AU UNVERSTET HEATH BRGTTE ORK SCHEMMER GCP-KOORDNATOR 22. OKTOBER 2015
12 WHAT CAME UP N SEPT. 2014? Sponsor will select the inclusion/exclusion criteria which should be monitored. Biobanking was discussed Study drug was discussed Safety: An instruction for AE/SAE reporting should be prepared because this section in the protocol is complicated to read/understand due to the 2 companies requests of specific wordings. A list of contraindicated medicines which the monitors should check will be prepared by sponsor AU UNVERSTET HEATH BRGTTE ORK SCHEMMER GCP-KOORDNATOR 22. OKTOBER 2015
13 Contact to monitors to monitors via NORM contact list All responded positively nitial cost proposals Decision for local monitors except Sweden: 1 monitor due to economy
14 PHEMON TRA MEETNG NOV Skype meeting between sponsor and CTO Not to discuss monitoring but.. Among others it was decided, that there should be one monitoring plan for all the Nordic countries That the NORM template and guideline should be used That the risk assessment should be prepared by the GCP-unit and forwarded to the participating monitors for comments and their site assessment AU UNVERSTET HEATH BRGTTE ORK SCHEMMER GCP-KOORDNATOR 22. OKTOBER 2015
15 PREPARATON OF RAT AND NORM MONTORNG PAN Marianne and started all over or at least that's how it felt Working with RAT was a challenge - t took a while to get through it We tried to use the risk assessment already prepared in Danish and the knowledge from the meetings with sponsor and CTO We ended up with a version that was send to sponsor and CTO with more questions to ask and more issues to think about Yes it is a very patient sponsor Nothing new came up from this risk assessment, but the wording in RAT can be used in the monitoring plan AU UNVERSTET HEATH BRGTTE ORK SCHEMMER GCP-KOORDNATOR 22. OKTOBER 2015
16 PREPARATON OF RAT AND NORM MONTORNG PAN This final version dated was send by CTO to all of you who are participating in PHEMON for your comments We didn t get very many comments back why? Maybe because t is always a challenge to comment on a risk assessment if you have never done one yourself You are busy with a lot of other studies and PHEMON is far ahead This was the first study using NORM s RAT Or? AU UNVERSTET HEATH BRGTTE ORK SCHEMMER GCP-KOORDNATOR 22. OKTOBER 2015
17 CTO thoughts Very convenient to be able to contact all monitors via the NORM network Very convenient to have only one monitoring plan National requirements in appendix 1a: very few issues
18 National requirements Sweden: Norway: Finland: Denmark: Specifies local SOP to use C signature by patient not any legal representative Specifies local SOP to use Timeline for response to discrepancies Assessment of site s experience Specifies local SOP to use Monitoring costs and invoicing is described Assessment of site s experience
19 DD WE EARN SOMETHNG? f it is possible, then a risk assessment should always be made in cooperation with sponsor We think the Danish risk assessment helped sponsor to think about some issues in the protocol and in the preparation of study procedures As we can see RAT didn t add anything extra to this, but probably would have, if it had been the first risk assessment To be able to use RAT takes some practice especially the first couple of times But it is a great guideline with a lot of explanation But be prepared it is very time consuming AU UNVERSTET HEATH BRGTTE ORK SCHEMMER GCP-KOORDNATOR 22. OKTOBER 2015
20 CTO conclusion Be prepared we want to do it again
21 AU UNVERSTET
SOP16: Standard Operating Procedure for Establishing Sites and Centres - Site Setup
SOP16: Standard Operating Procedure for Establishing Sites and Centres - Site Setup Authorship Team: Leanne Quinn for Joint SOP Group on Trial Processes (viz Ian Russell, Anne Seagrove, Jemma Hughes, Yvette
More informationUnofficial copy not valid
Page 2 (9) CONTENTS 1. PURPOSE... 3 2. DEFINITIONS... 3 3. RESPONSIBILITY... 3 4. INVESTIGATOR SELECTION... 3 4.1 Identification of Investigator s... 3 4.2 Initial Contacts... 4 4.3 Distribution of Pre-Study
More informationDocument Title: File Notes. Document Number: 024
Document Title: File Notes Document Number: 024 Version: 1.2 Ratified by: Committee Date ratified: 03/10/2017 Name of originator/author: Directorate: Department: Name of responsible individual: Rachel
More informationStandard Operating Procedures
Clinical Monitoring and Site Verification Procedure Overview To define the standard procedures for preparation and documentation of site visits for clinical monitoring and spoke verification for any NETT
More informationDocument Title: Research Database Application (ReDA) Document Number: 043
Document Title: Research Database Application (ReDA) Document Number: 043 Version: 1.1 Ratified by: Committee Date ratified: 23 February 2017 Name of originator/author: Rachel Fay Directorate: Medical
More informationAuditing of Clinical Trials
Version 1.2 Effective date: 3 September 2012 Author: Approved by: Claire Daffern, QA Manager Dr Sarah Duggan, CTU Manager Revision Chronology: Effective Date Version 1.2 3 Sept 2012 Version 1.1 12 May
More informationDocument Title: Site Selection and Initiation for RFL Sponsored Studies Document Number: 026
Document Title: Site Selection and Initiation for RFL Sponsored Studies Document Number: 026 Version: 1.1 Ratified by: Committee Date ratified: 03/10/2017 Name of originator/author: Directorate: Department:
More informationNEWCASTLE CLINICAL TRIALS UNIT STANDARD OPERATING PROCEDURES
NEWCASTLE CLINICAL TRIALS UNIT STANDARD OPERATING PROCEDURES SOP details SOP title: Site Selection and Initiation SOP number: TM 005 SOP category: Trial Management Version number: 03 Version date: 19 December
More informationGUIDELINES ON PARTICIPATION IN EU EXTERNAL AID PROGRAMMES
GUIDELINES ON PARTICIPATION IN EU EXTERNAL AID PROGRAMMES LENE TOPP, MANAGEMENT CONSULTING EUROPEAN CONSULTING - WITH A NORDIC STARTING POINT RMC Denmark RMC Germany RMC Sweden RMC Norway RMC Finland Project
More informationGood Clinical Practice. Lisa de Blieck MPA CCRC Clinical Trials Coordination Center
Good Clinical Practice Lisa de Blieck MPA CCRC Clinical Trials Coordination Center Good Clinical Practice (GCP) An international standard for the design, conduct, performance, monitoring, auditing, recording,
More informationDocument Title: GCP Training for Research Staff. Document Number: SOP 005
Document Title: GCP Training for Research Staff Document Number: SOP 005 Version: 2 Ratified by: Version 2, 04/10/2017 Page 1 of 13 Committee Date ratified: 26/10/2017 Name of originator/author: Directorate:
More informationNEWCASTLE CLINICAL TRIALS UNIT STANDARD OPERATING PROCEDURES
NEWCASTLE CLINICAL TRIALS UNIT STANDARD OPERATING PROCEDURES SOP details SOP title: Risk Assessment of NCTU Studies SOP number: TM-020 SOP category: Trial Management Version number: 02 Version date: 16
More informationPreliminary Questionnaire
Preliminary Questionnaire The purpose of the Preliminary Questionnaire is to assist the REB and the Qualification Team in preparing for the on-site review process. Please complete and sign the Preliminary
More informationHertfordshire Hospitals R&D Consortium Incorporating West Herts Hospitals NHS Trust and East & North Herts NHS Trust
Hertfordshire Hospitals R&D Consortium Incorporating West Herts Hospitals NHS Trust and East & North Herts NHS Trust STANDARD OPERATING PROCEDURE FOR RESEARCH Definition of Responsibilities for Externally
More informationNEWCASTLE CLINICAL TRIALS UNIT STANDARD OPERATING PROCEDURES
NEWCASTLE CLINICAL TRIALS UNIT STANDARD OPERATING PROCEDURES SOP details SOP title: Site Selection and Initiation SOP number: TM-005 SOP category: Trial Management Version number: 04 Version date: 10 July
More informationDocument Title: Research Database Application (ReDA) Document Number: 043
Document Title: Research Database Application (ReDA) Document Number: 043 Version: 1 Ratified by: Committee Date ratified: 30 September 2014 Name of originator/author: Directorate: Department: Name of
More information20 STEPS FROM STUDY IDEA INCEPTION TO PUBLISHING RESEARCH/ Evidence-Based Practice
20 STEPS FROM STUDY IDEA INCEPTION TO PUBLISHING RESEARCH/ Evidence-Based Practice Nursing Research/ Evidence-Based Practice Checklist (Version 31 January 2012) Specify the date in the left column when
More informationBuilding Quality into Clinical Trials. Amy C. Hoeper, MSN, RN, CCRC, Quality Manager Cincinnati Children s Gamble Program for Clinical Studies
Building Quality into Clinical Trials Amy C. Hoeper, MSN, RN, CCRC, Quality Manager Cincinnati Children s Gamble Program for Clinical Studies Objectives Identify strategies for developing a Quality Management
More informationStandard Operating Procedures (SOP) Research and Development Office
Standard Operating Procedures (SOP) Research and Development Office Title of SOP: Maintaining Training Records SOP Number: 20 Version Number: 2.0 Supercedes: 1.0 Effective date: August 2013 Review date:
More informationStudy Monitoring Plan Template
Study Monitoring Plan Template Sponsor Reference Number: Study Title: Principal Investigator: Study Centre: The Sponsor risk assessment form and the trial risk based monitoring strategy appendices 2 &
More informationConducting Academic Trials Under EU Law The EBMT Experience. Zoë Doran Director, Clinical Trials Operations EBMT
Conducting Academic Trials Under EU Law The EBMT Experience Zoë Doran Director, Clinical Trials Operations EBMT Sponsorship Major Challenges The Approval Process Monitoring/Quality Assurance Support Infrastructure
More informationCLIC Clinical Investigator (And Site Staff) Certification
CLIC Clinical Investigator (And Site Staff) Certification CLIC Level 1: 23-24 March 2015 CLIC Level 2: 25-27 March 2015 Cape Town (Venue to be confirmed) C PD points L e v e l 1 : 1 4 G e n e r a l, 2
More informationQuality and Informed Consent Procedures
Quality and Informed Consent Procedures. GZA hospitals is a member of Iridium Cancer Network Partner Hospitals Iridium Cancer network: GZA ziekenhuizen AZ KLINA AZ Nikolaas AZ Monica AZ Sint-Jozef Malle
More informationConducting Monitoring Visits for Investigator-Initiated Trials (IITs)
Conducting Monitoring Visits for Investigator-Initiated Trials (IITs) Clinical Research Coordinator Society (CRCS) Forum 25 July 2014 Xia Yu Clinical Research Associate Singapore Clinical Research Institute
More informationSOP-QA-28 V2. Approver: Prof Maggie Cruickshank, R&D Director Approver: Prof Steve Heys, Head of School
Title: Effective Date: 1-4-17 Review Date: 1-4-20 Author: Richard Cowie, QA Manager QA Approval: Richard Cowie, QA Manager Approver: Prof Maggie Cruickshank, R&D Director Approver: Prof Steve Heys, Head
More informationGuidance for the Applicants: Gilead Sciences Nordic Fellowship Programme 2017
Guidance for the Applicants: Gilead Sciences Nordic Fellowship Programme 2017 This is the fifth year of the Gilead Sciences Nordic Fellowship Programme. Applications are invited from health-care organisations
More informationGCP: Investigator Responsibilities. Susan Tebbs Nicola Kaganson
GCP: Investigator Responsibilities Susan Tebbs Nicola Kaganson Investigator Responsibilities Qualifications & agreements Resources Responsibilities to the subject Ethics The protocol The IMP & randomisation
More informationMANAGEMENT OF PROTOCOL AND GCP DEVIATIONS AND VIOLATIONS
MANAGEMENT OF PROTOCOL AND GCP DEVIATIONS AND VIOLATIONS DOCUMENT NO.: CR010 v4.0 AUTHOR: Heather Charles ISSUE DATE: 01 September 2016 EFFECTIVE DATE: 15 September 2016 1 INTRODUCTION 1.1 The Academic
More information1. INTRODUCTION 2. SCOPE 3. PROCESS
1. INTRODUCTION This document describes the procedure for establishing and maintaining records for staff training and complies with the principles of good clinical practice (GCP) for clinical trials of
More informationSTANDARD OPERATING PROCEDURE
STANDARD OPERATING PROCEDURE Title Reference Number End of Study Report SOP-RES-027 Version Number 2 Issue Date 15 Apr 2016 Effective Date 26 May 2016 Review Date 26 May 2018 Author(s) Reviewer(s) Natalie
More informationmanaging or activities.
STANDARD OPERATING PROCEDURE Clinical Research Monitoring TITLE: Site Initiation Visit TITLE: Site Initiation Visit 1. PURPOSE SOP Number: Version: 1.0 MICHR CRM MON 002 Effective Date: 19Dec2013 1.1 This
More informationTrial set-up, conduct and Trial Master File for HEY-sponsored CTIMPs
R&D Department Trial set-up, conduct and Trial Master File for HEY-sponsored CTIMPs Hull And East Yorkshire Hospitals NHS Trust 2010 All Rights Reserved No part of this document may be reproduced, stored
More informationSOP MONITORING & OVERSIGHT OF RESEARCH ACTIVITY. Contact Jess Bisset, Research Operations Manager x20227
SOP MONITORING & OVERSIGHT OF RESEARCH ACTIVITY SETTING FOR STAFF QUERIES Trust wide All staff involved in research Contact Jess Bisset, Research Operations Manager x20227 Guidance 1. Introduction In accordance
More informationSponsor Responsibilities. Roles and Responsibilities. EU Directives. UK Law
EU Directives Pharmacovigilance Legislation, SOPs and Reporting Louise Boldy, Governance & Safety Manager David Martin, Pharmacovigilance Monitor EU Legislation 2001/20/EC 2005/28/EC EudraLex Vol 10 UK
More informationLOUIS STOKES CLEVELAND VA MEDICAL CENTER RESEARCH SERVICE Human Subject Protection Standard Operating Procedure (SOP)
LOUIS STOKES CLEVELAND VA MEDICAL CENTER RESEARCH SERVICE Human Subject Protection Standard Operating Procedure (SOP) Effective Date: February 7, 2013 SOP Title: Study Monitoring Visits - Process for Access
More informationGCP INSPECTION CHECKLIST
(This list is not all inclusive; item may be added &/or deleted as per the Study/Site/Sponsor/Lab) I. General. Name and address of the clinical trial site Tel. No. & e- mail:. Date of Inspection. Inspection
More informationGuideline for the notification of serious breaches of Regulation (EU) No 536/2014 or the clinical trial protocol
1 2 31 January 2017 EMA/430909/2016 3 4 5 Guideline for the notification of serious breaches of Regulation (EU) No 536/2014 or Draft Adopted by GCP Inspectors Working Group (GCP IWG) 30 January 2017 Adopted
More informationRisk Assessment and Monitoring
Version 1.3 Effective date: 25 May 2012 Author: Approved by: Claire Daffern, QA Manager Dr Sarah Duggan, CTU Manager Revision Chronology: Effective Date Version 1.3 25 May 2012 Version 1.2 29 January 2010
More informationStandard Operating Procedure (SOP) Research and Development Office
Standard Operating Procedure (SOP) Research and Development Office Title of SOP: Routine Project Audit SOP Number: 6 Version Number: 2.0 Supercedes: 1.0 Effective date: August 2013 Review date: August
More informationDocument Title: Study Data SOP (CRFs and Source Data)
Document Title: Study Data SOP (CRFs and Source Data) Document Number: SOP047 Staff involved in development: Job titles only Document author/owner: Directorate: Department: For use by: RM&G Manager, R&D
More informationNORITS - Nordic Interoperable Tolling Systems
NORITS - Nordic Interoperable Tolling Systems Jacob Trondsen MSc Eng. Senior Adviser Norwegian Public Roads Administration (NPRA) 0033 Oslo, Norway Tel (direct line): +47 22 07 30 10 / E-mail: Jacob.trondsen@vegvesen.no
More informationStandard Operating Procedure (SOP) Research and Development Office
Standard Operating Procedure (SOP) Research and Development Office Title of SOP: Recording and Reporting Deviations, Violations, Potential Serious Breaches, Serious Breaches and Urgent Safety Measures
More informationWENDWG Issues to NHC58
Nordic Hydrographic Commission WENDWG Issues to NHC58 18-20 August 2014 Helsinki, Finland Jens Peter Hartman Jarmo Mäkinen 18 August 2014 Contents WENDWG Work WENDWG4 Meeting on 18-19 March 2014 Revision
More informationNordplus. - the new programme period. Susanne Suhr Andersen Danish Agency for Science and Higher Education ICM FORUM 2017
Nordplus - the new programme period Susanne Suhr Andersen Danish Agency for Science and Higher Education ICM FORUM 2017 Nordplus Next programme period spans over 5 years: 2018-2022 Nordplus The overall
More informationDocument Title: Recruiting Process. Document Number: 011
Document Title: Recruiting Process Document Number: 011 Version: 1.0 Ratified by: Committee Date ratified: 24.06.2014 Name of originator/author: Directorate: Department: Name of responsible individual:
More informationETHICS COMMITTEE: ROLE, RESPONSIBILITIES AND FUNCTIONS K.R.CHANDRAMOHANAN NAIR DEPARTMENT OF ANATOMY, MEDICAL COLLEGE, THIRUVANANTHAPURAM
ETHICS COMMITTEE: ROLE, RESPONSIBILITIES AND FUNCTIONS K.R.CHANDRAMOHANAN NAIR DEPARTMENT OF ANATOMY, MEDICAL COLLEGE, THIRUVANANTHAPURAM Outline Introduction Composition Responsibilities of IEC Responsibilities
More informationStandard Operating Procedure (SOP)
Standard Operating Procedure MANAGEMENT OF BREACHES IN RESEARCH SETTING AUDIENCE ISSUE Trustwide for research sponsored by UHBristol All research staff involved in UH Bristol sponsored research This SOP
More informationWhy do we need an addendum to ICH E6?
Addendum to ICH E6 Hideaki Ui, Ph.D. Inspection Director Office of Non-clinical and Clinical Compliance Pharmaceuticals and Medical Devices Agency, Japan Disclaimer The views and opinions expressed in
More informationResearch & Development. Case Report Form SOP. J H Pacynko and J Illingworth. Research, pharmacy and R&D staff
Department Title of SOP Research & Development Case Report Form SOP SOP reference no: R&D GCP SOP 03 Authors: Current version number and date: J H Pacynko and J Illingworth Version 2, 01.02.18 Next review
More informationThe GCP Perspective on Study Monitoring
The GCP Perspective on Study Monitoring Heidi Judge, CCRP Sr. Clinical Trials Project Manager Clinical Trials Network and Institute Massachusetts General Hospital 1 Overview Monitoring Basics Who, What,
More informationOffice of the Vice Chancellor for Research Supervisory Responsibilities of Clinical Investigators
Office of the Vice Chancellor for Research Supervisory Responsibilities of Clinical Investigators Patricia Fischer, RN, CCRP Investigator Responsibilities FDA Draft Guidance May 2007 Clarifies FDA s expectations,
More informationStandard Operating Procedure (SOP) for Reporting Serious Breaches in Clinical Research
Standard Operating Procedure (SOP) for Reporting Serious Breaches in Clinical Research For Completion by SOP Author Reference Number PHT/RDSOP/002 Version V2.0 07 Apr 2016 Document Author(s) Document Reviewer(s)
More informationAdverse Event Reporting
Adverse Event Reporting The current version of all Hillingdon Hospital R&D Guidance Documents and Standard Operating Procedures are available from the R&D Intranet and Internet sites: www.thh.nhs.uk/departments/research/research.htm
More informationDr. R. Sathianathan. Role & Responsibilities of Principal Investigators in Clinical Trials. 18 August 2015
18 August 2015 Role & Responsibilities of Principal Dr. R. Sathianathan Professor of Psychiatry, SRMC, Porur & Former Director, Institute of Mental Health, Chennai Principal Investigators & GOOD CLINICAL
More informationInvestigator Site File Standard Operating Procedure (SOP)
Investigator Site File Standard Operating Procedure (SOP) DOCUMENT CONTROL: Version: 1 Ratified by: Quality and Safety Sub Committee Date ratified: 30 January 2017 Name of originator/author: Research Nurse
More informationInitially Submitted on 11/24/2009 Final Submission By Test6 CA on 11/24/2009 1:51 PM Approval By student13 student13 on 11/24/2009 1:52 PM Attendees
Location: Los Angeles Research Institute: Los Angeles, CA Investigation Product/Test Article: Laftr Visit Mechanism: On-site Initially Submitted on 11/24/2009 Final Submission By Test6 CA on 11/24/2009
More informationHur du effektivt genomför dina studier med hjälp av elektroniska CRF
Hur du effektivt genomför dina studier med hjälp av elektroniska CRF Maria Öhlander, Director Clinical Operations, Karo Bio Sverre Bengtsson, VP Business Development, PCG Current problems in clinical trials
More informationChecklist prior to recruiting first patient
Pre-Site selection Site Initiation Visit (SIV) What kind of questions should you ask How you should prepare for this visit Delegation logs Training logs ECRF/CRF Checklist prior to recruiting first patient
More informationDocumenting the Story of a Clinical Trial: Concept to CAPA. Lori T. Gilmartin Gilmartin Consulting LLC
Documenting the Story of a Clinical Trial: Concept to CAPA Lori T. Gilmartin Gilmartin Consulting LLC The regulations represent the floor while ethical thinking is the sky. Dr. Thomas Moore Boston University
More informationInvestigator-Initiated Studies: When you re the Sponsor. Cheri Robert & Tammy Mah-Fraser
Investigator-Initiated Studies: When you re the Sponsor Cheri Robert & Tammy Mah-Fraser ACRC Clinical Research Conference Edmonton, AB October 15, 2014 Session Objectives Define roles of the investigator,
More informationUNIVERSITY OF TENNESSEE HEALTH SCIENCE CENTER INSTITUTIONAL REVIEW BOARD REPORTING UNANTICIPATED PROBLEMS INCLUDING ADVERSE EVENTS
UNIVERSITY OF TENNESSEE HEALTH SCIENCE CENTER INSTITUTIONAL REVIEW BOARD REPORTING UNANTICIPATED PROBLEMS INCLUDING ADVERSE EVENTS I. PURPOSE To specify the procedures for reporting unanticipated problems,
More informationDeloitte Shared Services, GBS & BPO Conference
Deloitte Shared Services, GBS & BPO Conference Focus 13: Danske Bank Creating real impact and change with Continuous Improvement by using it as a tool to work beyond the boundaries of shared services Rosita
More informationNordic Innovation House-NY & Entrepreneurial Marketing Program for Nordic Creative Industries
Nordic Innovation House-NY & Entrepreneurial Marketing Program for Nordic Creative Industries No city in the world epitomizes sales, marketing and branding like New York City background There is a need
More informationStudy Initiation Meeting
Puerto Rico Clinical and Translational Research Consortium Study Initiation Meeting I. Procedure Title: Study Initiation Meeting II. Overview/Procedure Description: 1. The Clinical Research Resources and
More informationHIMSS Europe ANNUAL SURVEY 2016
HIMSS Europe ANNUAL SURVEY 2016 TABLE OF CONTENT HIMSS EUROPE Who we are... page 3 Survey overview... page 4 Results Overall... page 10 Priorities in healthcare IT... page 11 Trends in healthcare IT...
More informationMonitoring Clinical Trials
This is a controlled document. The master document is posted on the JRCO website and any print-off of this document will be classed as uncontrolled. Researchers and their teams may print off this document
More informationThe Erasmus+ grants for academic year are allocated as follows:
Oulu, Aug 22, 2017 DEAR ERASMUS+ EXCHANGE STUDENT, Congratulations, you are accepted as an Erasmus exchange student on behalf of the University of Oulu! Below, you will find detailed information of what
More informationSTANDARD OPERATING PROCEDURE
STANDARD OPERATING PROCEDURE Title Reference Number Corrective and Preventative Action SOP-QMS-008 Version Number 2 Issue Date 29 th Sep 2016 Effective Date 10 th Nov 2016 Review Date 10 th Nov 2018 Author(s)
More informationVCU Clinical Research Quality Assurance Assessment
VCU Clinical Research Quality Assurance Assessment Principal Investigator Protocol Title Protocol IRB Number Name of Person Completing Assessment Date Assessment was Completed The goal of this assessment
More informationStandard Operating Procedure. Essential Documents: Setting Up a Trial Master File. SOP effective: 19 February 2016 Review date: 19 February 2018
Standard Operating Procedure SOP number: SOP full title: SOP-JRO-06-003 Essential Documents: Setting Up a Trial Master File SOP effective: 19 February 2016 Review date: 19 February 2018 SOP author signature:
More informationTrial Management: Trial Master Files and Investigator Site Files
Title: Outcome Statement: Written By: Trial Management: Trial Master Files and Investigator Site Files Staff working on research studies in NSFT will be informed about the requirements of setting up and
More informationStandard Operating Procedure (SOP) Research and Development Office
Standard Operating Procedure (SOP) Research and Development Office Title of SOP: Delegated Responsibilities in Research Projects SOP Number: 11 Version Number: 2.0 Supercedes: 1.0 Effective date: August
More informationClinical Study Risk Assessment
Clinical Study Risk Assessment Clinical S.O.P. No.: 19 Compiled by: Approved by: Review date: November 2016 DOCUMENT HISTORY Version Detail of purpose / change Author / edited number by 1.0 New SOP Shona
More informationSuggestions for Modification of the Clinical Trials Directive ELN Annual Meeting 01 February 2011
Suggestions for Modification of the Clinical Trials Directive ELN Annual Meeting 01 February 2011 European Medical Research Councils Dr Kirsten Steinhausen 1 ESF Member Organisations ESF is an independent
More informationJoint R&D Support Office SOP S-2011 UHL
UNIVERSITY OF LEICESTER & UNIVERSITY HOSPITALS OF LEICESTER NHS TRUST JOINT RESEARCH & DEVELOPMENT SUPPORT OFFICE STANDARD OPERATING PROCEDURES Joint R&D Support Office SOP S-2011 UHL Site Initiation for
More informationOnce the feasibility assessment has been conducted the study team will be notified via (Appendix 3) of the outcome and whether the study is;
1. INTRODUCTION 2. SCOPE Feasibility assessments will ascertain any operational concerns about a research study which may delay NHS Permission or cause issues with study delivery. By conducting an assessment
More informationFUDAN UNIVERSITY S VISION AND STRATEGY FOR GLOBAL EDUCATION SWEDEN COOPERATION. Chen Yinzhang June, 2014
FUDAN UNIVERSITY S VISION AND STRATEGY FOR GLOBAL EDUCATION SWEDEN COOPERATION Chen Yinzhang June, 2014 Brief Information of Fudan University Founded in 1905 With around 30000 students, 10% international
More informationNIHR Research for Patient Benefit (RfPB) Application Process
Research Department, Sheffield STANDARD OPERATING PROCEDURE NIHR Research for Patient Benefit (RfPB) Application Process SOP History None SOP Number SOPC114 Created Clinical Research Office Sheffield SUPERSEDED
More informationRoyal Children s Hospital- Melbourne Information Session
Royal Children s Hospital- Melbourne Information Session The Role of the Lead Site: a CRO Perspective Rebecca Nuhiu PPD Australia Pty Ltd, Associate Country Manager, SIA-ANZ THE ROLE OF THE CRO IN NMA
More informationSOP18b: Standard Operating Procedure for Preparing for External Audit and Inspection
SOP18b: Standard Operating Procedure for Preparing for External Audit and Inspection Authorship Team: Jemma Hughes, Tina Morgan, for Joint SOP Group on Trial Processes (viz Leanne Quinn, Ian Russell, Anne
More informationSite Closedown Checklist for UoL Sponsored CTIMP Studies
Site Closedown Checklist for UoL Sponsored CTIMP Studies Site Information Site: Study Title: UoL study number: Centre name: Investigator: Date of Visit: Date of Report Date Responses due by: List of site
More informationACTIONS/PSOP/001 Version 1.0 Page 2 of 6
1. The purpose of the Pharmacy Site File To enable the designated trust pharmacy to fulfil its role and exercise appropriate control over all aspects of study medication handling, an accurately maintained
More informationExperiences with national standardization of research information systems in Scandinavia
Experiences with national standardization of research information systems in Scandinavia Gunnar Sivertsen Nordic Institute for Studies in Innovation, Research and Education, Oslo, Norway Overview of this
More informationSTANDARD OPERATING PROCEDURE SOP 325
STANDARD OPERATING PROCEDURE SOP 325 STUDY START UP ACTIVITIES FOR CLINICAL RESEARCH TRIALS Version 1.4 Version date 28.03.2017 Effective date 28.03.2017 Number of pages 7 Review date April 2019 Author
More informationDocument Title: Version Control of Study Documents. Document Number: 023
Document Title: Version Control of Study Documents Document Number: 023 Version: 1.1 Ratified by: Committee Date ratified: 03 OCT 2017 Name of originator/author: Directorate: Department: Name of responsible
More informationNIHR Research for Patient Benefit (RfPB) Application Process
Research Department, Sheffield STANDARD OPERATING PROCEDURE NIHR Research for Patient Benefit (RfPB) Application Process SOP Number C114 Version Number 8.0 Date effective 20/12/2014 Author Daniel Lawrence
More informationCOMPETENCY FRAMEWORK
COMPETENCY FRAMEWORK Theresa Ledger Lead Nurse Research and Development Clinical Research Facility Sheffield C:\Documents and Settings\Robertus\My Documents\Mariann\CRF\CRF Portfolio and Competency Template_DRAFT
More informationEthics Committee Composition Roles & Responsibilities. Dr Girish Dayma Dr Sanjay Juvekar KEM Hospital Research Centre Pune
Ethics Committee Composition Roles & Responsibilities Dr Girish Dayma Dr Sanjay Juvekar KEM Hospital Research Centre Pune Outline Introduction Composition Roles & Responsibilities Overview of amendment
More informationMHRA Findings Dissemination Joint Office Launch Jan Presented by: Carolyn Maloney UHL R&D Manager
MHRA Findings Dissemination Joint Office Launch Jan. 2012 Presented by: Carolyn Maloney UHL R&D Manager Purpose of presentation To feed back abridged findings from March 2011 MHRA Statutory Systems Inspection
More informationPROMPTLY REPORTABLE EVENTS
PROMPTLY REPORTABLE EVENTS PURPOSE AND SCOPE To define the structure and responsibility for reporting unanticipated problems that occurs during the conduct of research. APPLICABLE REGULATIONS Policy II.02
More informationNORDIC COLLABORATIONS ON REGISTRIES SIMILARITIES & DIFFERENCES
NORDIC COLLABORATIONS ON REGISTRIES SIMILARITIES & DIFFERENCES Tina Lidén Mascher, R.N., Degree in Physioth., MBA Strategist International projects and collaborations with the industry Health and Social
More informationDOCUMENT DRAIN. How Back-Office Processes are Shredding Productivity
DOCUMENT DRAIN How Back-Office Processes are Shredding Productivity 1. Who Did We Survey? Age Seniority 18-24 25-34 35-54 55+ Junior Senior or Executive Decision Makers 52% 47% Company size* Industries
More informationTHE NORDIC LIST. An international collaborative tool for publication analysis with relevance for open access
THE NORDIC LIST An international collaborative tool for publication analysis with relevance for open access Background Funders and decision makers want to be able to overview a country s or organisation
More informationQuality Assurance in Clinical Research at RM/ICR. GCP Compliance Team, Clinical R&D
Quality Assurance in Clinical Research at RM/ICR GCP Compliance Team, Clinical R&D Slide 1 of 13 What is Quality Assurance? The maintenance of a desired level of quality in a service or product, especially
More informationStandard Operating Procedure INVESTIGATOR OVERSIGHT OF RESEARCH. Chief and Principal Investigators of research sponsored and/or hosted by UHBristol
Standard Operating Procedure INVESTIGATOR OVERSIGHT OF RESEARCH SETTING FOR STAFF ISSUE Trustwide Chief and Principal Investigators of research sponsored and/or hosted by UHBristol Oversight of research
More informationPLATELET-ORIENTED INHIBITION ISCHEMIC STROKE (POINT) MONITORING PLAN IN NEW TIA AND MINOR. Version 2.0 Updated 11 May 2017
PLATELET-ORIENTED INHIBITION IN NEW TIA AND MINOR ISCHEMIC STROKE (POINT) MONITORING PLAN Version 2.0 Updated 11 May 2017 Monitoring Plan Table of Contents 1.0 Introduction... 4 2.0 Purpose... 4 3.0 Review
More informationDocument Title: Training Records. Document Number: SOP 004
Document Title: Training Records Document Number: SOP 004 Version: 1 Ratified by: RFL Committee Date ratified: 03.06.2014 Name of originator/author: Directorate: Department: Name of responsible individual:
More informationProgramme Outline BACKGROUND
Youth in Europe A Drug Prevention Programme Programme Outline BACKGROUND The Advisory Board Meeting of European Cities against Drugs (ECAD) held in Rimini, Italy, on February 4, 2005, agreed to propose
More informationDocument Title: Informed Consent for Research Studies
Document Title: Informed Consent for Research Studies Document Number: SOP003 Staff involved in development: Job titles only Document author/owner: Directorate: Department: For use by: RM&G Manager, R&D
More informationIN ACCORDANCE WITH THIS INTERNATIONAL DEVICE STANDARD
COMPLIANCE WITH ISO 14155:2011 GUIDANCE FOR ENSURING YOUR CLINICAL STUDY IS BEING DESIGNED, EXECUTED, AND MONITORED IN ACCORDANCE WITH THIS INTERNATIONAL DEVICE STANDARD Introduction: An increasing trend
More information